$ATOS
ATOSSA THERAPEUTICS, INC.

2021 Q3 Form 10-Q Financial Statement

#000143774921019810 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.952M $3.205M $2.280M
YoY Change 59.59% 40.58% -51.18%
% of Gross Profit
Research & Development $2.206M $3.799M $1.653M
YoY Change 32.98% 129.79% -36.7%
% of Gross Profit
Depreciation & Amortization $6.220K $5.050K $10.00K
YoY Change -68.9% -49.5% -50.0%
% of Gross Profit
Operating Expenses $5.159M $7.004M $3.936M
YoY Change 47.02% 77.96% -45.98%
Operating Profit -$5.159M -$7.004M -$3.936M
YoY Change 47.02% 77.96% -45.98%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$38.55K -$35.00K $29.67K
YoY Change -317.25% -217.98% 26.02%
Pretax Income -$5.197M -$7.039M -$3.906M
YoY Change 48.87% 80.2% -46.22%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.197M -$7.039M -$3.906M
YoY Change 48.87% 80.2% -46.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 -$0.06
Diluted Earnings Per Share -$41.07K -$57.90K -$425.5K
COMMON SHARES
Basic Shares Outstanding 126.6M 121.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.0M $142.4M $7.500M
YoY Change 1438.91% 1799.11% -56.14%
Cash & Equivalents $140.0M $142.4M $7.463M
Short-Term Investments
Other Short-Term Assets $18.06K $78.88K $264.0K
YoY Change -89.91% -70.12% 188440.71%
Inventory
Prepaid Expenses $1.883M $2.392M $1.464M
Receivables
Other Receivables
Total Short-Term Assets $143.0M $145.8M $10.06M
YoY Change 1163.32% 1349.37% -45.28%
LONG-TERM ASSETS
Property, Plant & Equipment $22.14K $14.50K $29.44K
YoY Change -12.94% -50.74% -33.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.41K $13.41K $17.22K
YoY Change -22.13% -22.13% 0.0%
Total Long-Term Assets $36.76K $37.09K $144.0K
YoY Change -69.2% -74.25% -34.88%
TOTAL ASSETS
Total Short-Term Assets $143.0M $145.8M $10.06M
Total Long-Term Assets $36.76K $37.09K $144.0K
Total Assets $143.0M $145.9M $10.21M
YoY Change 1150.46% 1329.28% -45.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $668.0K $537.9K $1.033M
YoY Change -2.14% -47.91% 224.48%
Accrued Expenses $75.70K $531.6K $92.86K
YoY Change -11.13% 472.51% 73.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.676M $1.796M $1.827M
YoY Change 7.06% -1.67% 76.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.676M $1.796M $1.827M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.676M $1.796M $1.831M
YoY Change 6.97% -1.93% 73.29%
SHAREHOLDERS EQUITY
Retained Earnings -$124.4M -$119.2M -$100.9M
YoY Change 19.14% 18.11% 14.47%
Common Stock $265.2M $262.7M $108.7M
YoY Change 133.29% 141.73% 3.46%
Preferred Stock $626.0K
YoY Change -7.4%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.3M $144.1M $8.374M
YoY Change
Total Liabilities & Shareholders Equity $143.0M $145.9M $10.21M
YoY Change 1150.46% 1329.28% -45.16%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$5.197M -$7.039M -$3.906M
YoY Change 48.87% 80.2% -46.22%
Depreciation, Depletion And Amortization $6.220K $5.050K $10.00K
YoY Change -68.9% -49.5% -50.0%
Cash From Operating Activities -$3.062M -$5.335M -$2.230M
YoY Change 14.24% 139.24% -10.8%
INVESTING ACTIVITIES
Capital Expenditures -$9.400K $0.00 -$10.00K
YoY Change -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.400K $0.00 -$10.00K
YoY Change -100.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 678.9K 10.19M 350.0K
YoY Change -84.28% 2812.67%
NET CHANGE
Cash From Operating Activities -3.062M -5.335M -2.230M
Cash From Investing Activities -9.400K 0.000 -10.00K
Cash From Financing Activities 678.9K 10.19M 350.0K
Net Change In Cash -2.392M 4.859M -1.890M
YoY Change -245.85% -357.11% -24.7%
FREE CASH FLOW
Cash From Operating Activities -$3.062M -$5.335M -$2.230M
Capital Expenditures -$9.400K $0.00 -$10.00K
Free Cash Flow -$3.052M -$5.335M -$2.220M
YoY Change 13.89% 140.32% -10.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4968 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3643921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2915000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
587
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
587
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
621
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
621
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125925096
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126623256
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125925096
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47548835
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47548835
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
178544 USD
CY2021Q1 atos Issuance Of Common Stock And Warrants Issuance Costs
IssuanceOfCommonStockAndWarrantsIssuanceCosts
5493310 USD
us-gaap Net Income Loss
NetIncomeLoss
-10577000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9745000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142433000 USD
CY2021Q2 atos Working Capital Deficit
WorkingCapitalDeficit
144035 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
112624000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42956000 USD
CY2020Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142432961 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39553671 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2391966 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1813902 USD
CY2021Q2 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
817109 USD
CY2020Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
634940 USD
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
78882 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
657662 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
145830918 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42770175 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14501 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20632 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4458 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13375 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4720 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18053 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13408 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218 USD
CY2021Q2 us-gaap Assets
Assets
145868005 USD
CY2020Q4 us-gaap Assets
Assets
42839453 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
537915 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1588613 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
531602 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
93367 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
700588 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963665 USD
CY2021Q2 atos Common Stock Warrant Lability
CommonStockWarrantLability
0 USD
CY2020Q4 atos Common Stock Warrant Lability
CommonStockWarrantLability
13003075 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4720 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18053 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21278 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4748 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1796103 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15671521 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
1 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
22666505 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8558778 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
240023345 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129887146 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119204948 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111898992 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
144071902 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27167932 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145868005 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42839453 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3798636 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1653239 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5177123 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2591859 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3205130 USD
us-gaap Net Income Loss
NetIncomeLoss
-6853562 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1853861 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1724236 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-0 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2282568 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5357371 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4280957 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
7003766 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3935807 USD
us-gaap Operating Expenses
OperatingExpenses
10534494 USD
us-gaap Operating Expenses
OperatingExpenses
6872816 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7003766 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3935807 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10534494 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6872816 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35482 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29665 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42823 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19254 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7039248 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3906142 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10577317 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6853562 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7039248 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3906142 USD
us-gaap Net Income Loss
NetIncomeLoss
-10577317 USD
us-gaap Net Income Loss
NetIncomeLoss
-6853562 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
121572091
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9187588
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
107159698
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9159286
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13156005 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
687752 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2947420 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10896337 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
347627 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036484 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3906142 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
8374306 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27167932 USD
CY2021Q1 atos Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
69668408 USD
CY2021Q1 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
32760302 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
639751 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3538069 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
139701399 USD
CY2021Q2 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
10195641 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1214110 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7039248 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
144071902 USD
us-gaap Net Income Loss
NetIncomeLoss
-10577317 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-2226 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15048 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24711 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
578064 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
602022 USD
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
182169 USD
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
20966 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-582590 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
237827 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1050698 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
739536 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
438235 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
14967 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-263077 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-244012 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142432961 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7462736 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142542961 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7572736 USD
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
13003075 USD
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
0 USD
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 6, 2020, </em>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">Atossa Therapeutics, Inc. (the “Company”) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently developing its pharmaceuticals in the fields of oncology and infectious disease with a focus on treatments of the novel coronavirus ("COVID-<em style="font: inherit;">19"</em>), breast cancer and other breast conditions. The Company’s fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -18pt; text-align: justify; text-indent: 18pt;"><b>Impact of the Novel Coronavirus </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The continued spread of the COVID-<em style="font: inherit;">19</em> pandemic is affecting the United States and global economies and <em style="font: inherit;"> may </em>affect the Company’s operations and those of <em style="font: inherit;">third</em> parties on which the Company relies, including causing possible disruptions in the supply of the Company’s Endoxifen, AT-<em style="font: inherit;">H201,</em> AT-<em style="font: inherit;">301</em> and the conduct of current and future clinical trials. In addition, the COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the operations of the U.S. FDA and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<em style="font: inherit;">19</em> pandemic could also directly or indirectly impact the pace of enrollment in our clinical trials for at least the next several months and possibly longer as patients <em style="font: inherit;"> may </em>avoid or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to travel to healthcare facilities and physicians’ offices except for a health emergency. Such facilities and offices <em style="font: inherit;"> may </em>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<em style="font: inherit;">19</em> patients, and <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be available, in whole or in part, for clinical trial activities related to the Company's products under development. We have <em style="font: inherit;">not</em> experienced any delay in drug supply for our ongoing and planned clinical studies, including studies of Endoxifen, AT-<em style="font: inherit;">301</em> and AT-<em style="font: inherit;">H201.</em> However, our Phase <em style="font: inherit;">2</em> clinical study of Endoxifen that was being conducted in Australia was enrolling slower than expected due in part to COVID-<em style="font: inherit;">19</em> restrictions. Also, the study site we plan to use in Sweden has been negatively impacted by COVID-<em style="font: inherit;">19</em> restrictions which must be lifted before we can begin our study there. As a result, the study in Stockholm could be delayed or enroll more slowly than expected. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<em style="font: inherit;">19</em> pandemic is difficult to assess or predict, the impact of the COVID-<em style="font: inherit;">19</em> pandemic on the global financial markets <em style="font: inherit;"> may </em>reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-<em style="font: inherit;">19</em> pandemic is highly uncertain and subject to change. We do <em style="font: inherit;">not</em> yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company’s liquidity, capital resources, operations, financial position and business and those of the <em style="font: inherit;">third</em> parties on which we rely. We will continue to monitor future enrollment in studies for potential restrictions on site visits, mammograms or the impositions of new restrictions on trials as a result of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <em style="font: inherit;"> March 27, 2020. </em>On <em style="font: inherit;"> March 11, 2021, </em>President Biden signed an additional coronavirus relief package entitled the American Rescue Plan Act of <em style="font: inherit;">2021,</em> which included, among other things, provisions relating to stimulus payments to some Americans, extension of several CARES Act relief programs, expansion of the child tax credit, funding for vaccinations and other COVID-<em style="font: inherit;">19</em> related assistance programs. The CARES Act and the American Rescue Plan Act have <em style="font: inherit;">not</em> had a material impact on the Company; however, we will continue to examine the impacts that the CARES Act and the American Rescue Plan Act, as well as any future economic relief legislation, <em style="font: inherit;"> may </em>have on our business.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"/>
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129887146 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
16530 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-6704 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9745061 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5459417 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6610 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6610 USD
atos Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0 USD
atos Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
347627 USD
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
69668408 USD
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42955943 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112624351 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
347627 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102879290 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5118400 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39663671 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12691136 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142542961 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7572736 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139618860 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Use of Estimates</b></p> <p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020Q4 atos Common Stock Warrant Lability
CommonStockWarrantLability
13003075 USD
CY2021Q1 atos Common Stock Warrant Lability
CommonStockWarrantLability
0 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111898992 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108627631 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2021Q2 atos Research And Development Current
ResearchAndDevelopmentCurrent
1689936 USD
CY2020Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
1215834 USD
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
522178 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
417854 USD
CY2021Q2 atos Professional Services Current
ProfessionalServicesCurrent
122594 USD
CY2020Q4 atos Professional Services Current
ProfessionalServicesCurrent
128229 USD
CY2021Q2 atos Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
29000 USD
CY2020Q4 atos Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
0 USD
CY2021Q2 us-gaap Deposit Assets
DepositAssets
14218 USD
CY2020Q4 us-gaap Deposit Assets
DepositAssets
14218 USD
CY2021Q2 us-gaap Prepaid Rent
PrepaidRent
14040 USD
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
4488 USD
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
33279 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2391966 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1813902 USD
atos Research And Development Tax Rebate Receivable Additions
ResearchAndDevelopmentTaxRebateReceivableAdditions
271000 USD
atos Research And Development Tax Rebate Receivable Additions
ResearchAndDevelopmentTaxRebateReceivableAdditions
203000 USD
CY2021Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
396847 USD
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
689635 USD
CY2021Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
191714 USD
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
171112 USD
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
112027 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
102918 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
700588 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963665 USD
CY2021Q2 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22572854
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22572854
CY2021Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10196000 USD
CY2021Q2 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5091000
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
37155000
CY2021Q2 atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
5091000
atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
37155000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7039248 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3906142 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10577317 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6853562 USD
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
121572091
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9187588
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
107159698
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9159286
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35999018
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7246371
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34170429
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6407699
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
142266985 USD
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
39345260 USD
CY2021Q1 atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
750 USD
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
3300 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
13300 USD
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
14700 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
29400 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.113 pure
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4968 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
242 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3700 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
14388 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
14700 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
28200 USD
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6931 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12170 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4488 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
8873 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3643921
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2915000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1214110 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1036484 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1853861 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1724236 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7067436
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3643921
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.97
atos Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
96050 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10636357
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
44150423 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5552436
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M28D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
25562663 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10636357
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M15D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
44150423 USD

Files In Submission

Name View Source Status
0001437749-21-019810-index-headers.html Edgar Link pending
0001437749-21-019810-index.html Edgar Link pending
0001437749-21-019810.txt Edgar Link pending
0001437749-21-019810-xbrl.zip Edgar Link pending
atos-20210630.xsd Edgar Link pending
atos-20210630_cal.xml Edgar Link unprocessable
atos-20210630_def.xml Edgar Link unprocessable
atos-20210630_lab.xml Edgar Link unprocessable
atos-20210630_pre.xml Edgar Link unprocessable
atos20210630_10q.htm Edgar Link pending
atos20210630_10q_htm.xml Edgar Link completed
ex_257531.htm Edgar Link pending
ex_257532.htm Edgar Link pending
ex_257533.htm Edgar Link pending
ex_257534.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending